Comparison of Cytogenetic and Molecular Findings in Non-therapy Related Acute Myeloid Leukemia (AML) with Erythroid Predominance (EP) and Refractory Anemia with Excess Blasts (RAEB).

<p>Comparison of Cytogenetic and Molecular Findings in Non-therapy Related Acute Myeloid Leukemia (AML) with Erythroid Predominance (EP) and Refractory Anemia with Excess Blasts (RAEB).</p

Effects of the presence of erythroid predominance (EP) and diagnostic categories on overall survival.

<p>(A) Overall survival of patients in this study cohort stratified by the presence or absence of EP. (B) Overall survival of patients with erythroid predominance stratified by their diagnostic categories.</p

The presence of erythroid predominance (EP) is associated with better overall survival in AML-MRC patients, but not in t-AML/MDS patients.

<p>(A) Overall survival of patients with AML-MRC stratified by the presence or absence of EP. (B) Overall survival of patients with t-AML/MDS stratified by the presence or absence of EP.</p

Characteristics of Acute Myeloid Leukemia Patients at Time of Initial Diagnosis.

*<p>comparing between cases with and without EE;</p>†<p>comparing between diagnostic groups;</p><p># ≥3 cytogenetic aberrations.</p><p>N.A., not applicable; w/o, without; AEL, acute erythroid leukemia; AML-MRC, AML with myelodysplasia-related changes; EP, erythroid predominance; UKMRC, UK Medical Research Council.</p

Patient inclusion, overall adequacy for NGS, and reason inadequate for NGS.

<p>Footnote: NGS: Next generation sequencing. ^a DNA quantity < 10 ng. ^b Less than 20% tumor cellularity due to necrosis, fibrosis and quantity of tissue available for analysis.</p

Example of likelihood of adequacy score 2 (equivocal).

<p><b>(A)</b> Chest CT showing right lung nodule that is small and in location (behind rib) requiring angled approach <b>(B)</b> Arrow points to needle in right lung nodule. Small pneumothorax is noted.</p

Example of likelihood of adequacy score 3 (high).

<p><b>(A)</b> PET/CT showing right lung lesion that is large and FDG avid. Also, there is no aerated lung in the planned biopsy path. <b>(B)</b> Arrow points to needle in right lung mass.</p

Simultaneous <i>PIK3CA</i> and <i>KRAS</i> mutations.

<p>Wild-type <i>KRAS</i> (blue bar) and mutant <i>KRAS</i> (red bar) in: A. All tumor types (tested, n = 367); B. All cancers excluding colorectal cancers (tested, n = 270); C. Colorectal cancers (tested, n = 97); D. Ovarian cancers (tested, n = 46).</p

Patient age and days between biopsy and NGS request with adequacy for NGS of biopsy specimens.

<p>Patient age and days between biopsy and NGS request with adequacy for NGS of biopsy specimens.</p

Problematic lesion imaging characteristics affecting likelihood of adequacy score^a.

<p>Problematic lesion imaging characteristics affecting likelihood of adequacy score<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0189651#t001fn001" target="_blank">^a</a>.</p